![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 19, 2013 11:58:49 AM
However, the cash situation has been rather bleak up to relationship established with Dominion capital. There was too much risk and uncertainty as to LymPro's future success, did MANF work and how the bills were to get paid.
In the last 6 months, we have make substantial progress with obtaining funding (from Dominion), adding new strategic advisors, updating the investment community on the continued progress with LymPro, announced Orphan data for MANF, and many science abstracts have been posted and published reinforcing the likelihood that MANF has enormous potential.
In summary, this company has incredible potential on both the Drug development and Diagnostic side...and as the cash situation and balance sheet have been cleaned up...the PPS is starting to rise one again. GLTA!!!
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM